Role of GAS5 noncoding RNA in mediating the effects of rapamycin and its analogues on mantle cell lymphoma cells

Clinical Lymphoma, Myeloma and Leukemia

Volumn 14, Issue 6, 2014, Pages 468-473

  Mourtada Maarabouni, Mirna ^a   Williams, Gwyn T ^a  

^a KEELE UNIVERSITY   (United Kingdom)

Author keywords

Chemotherapy; MTOR; NcRNA; Non Hodgkin lymphoma; Rapamycin

Indexed keywords

EVEROLIMUS; GROWTH ARREST SPECIFIC 5 PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN; RAPAMYCIN; TEMSIROLIMUS; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; UNTRANSLATED RNA; ANTINEOPLASTIC ANTIBIOTIC; GAS5 LONG NON-CODING RNA, HUMAN; LONG UNTRANSLATED RNA; PROTEIN KINASE INHIBITOR; SMALL INTERFERING RNA; TARGET OF RAPAMYCIN KINASE;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER THERAPY; CELL SURVIVAL; CELL VIABILITY; CLINICAL ASSESSMENT; COLONY FORMING UNIT; CONTROLLED STUDY; DNA SYNTHESIS; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION; HUMAN; HUMAN CELL; MANTLE CELL LYMPHOMA CELL; RNA INTERFERENCE; SIGNAL TRANSDUCTION; T LYMPHOCYTE; THERAPY EFFECT; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; MANTLE CELL LYMPHOMA; METABOLISM; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, MANTLE-CELL; PROTEIN KINASE INHIBITORS; RNA INTERFERENCE; RNA, LONG NONCODING; RNA, SMALL INTERFERING; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84922682892     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2014.02.011     Document Type: Article

References (38)

1. Humala K, Younes A. Current and emerging new treatment strategies for mantle cell lymphoma. Leuk Lymphoma 2013; 54:912-21
2. Camara-Clayette V, Hermine O, Ribrag V. Emerging agents for the treatment of mantle cell lymphoma. Exp Rev Anticancer Ther 2012; 12:1205-15
3. Bertoni F, Ponzoni M. The cellular origin of mantle cell lymphoma. Int J Biochem Cell Biol 2007; 39:1747-53
4. Li Y, Zhu X, Gu J, et al. Anti-miR-21 oligonucleotide enhances chemosensitivity of leukemic HL60 cells to arabinosylcytosine by inducing apoptosis. Hematology 2010; 15:215-21
5. Schneider C, King RM, Philipson L. Genes specifically expressed at growth arrest of mammalian-cells. Cell 1988; 54:787-93
6. Williams GT, Farzaneh F. The use of gene function to identify the rate-limiting steps controlling cell fate. Cancer Immunol Immunother 2004; 53:160-5
7. Williams GT, Hughes JP, Stoneman V, et al. Isolation of genes controlling apoptosis through their effects on cell survival. Gene Ther Mol Biol 2006; 10B: 255-61
8. Mourtada-Maarabouni M, Hedge VL, Kirkham L, Farzaneh F, Williams GT. Growth arrest in human T-cells is controlled by the non-coding RNA growtharrest-specific transcript 5 (GAS5). J Cell Sci 2008; 121:939-46
9. Dong X, Rodriguez C, Guo P, et al. SnoRNA U50 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer. Hum Mol Genet 2008; 17:1031-42
10. Dong X, Guo P, Boyd J, et al. Implication of snoRNA U50 in human breast cancer. J Genet Genomics 2009; 36:447-54
11. Valleron W, Laprevotte E, Gautier E, et al. Specific small nucleolar RNA expression profiles in acute leukemia. Leukemia 2012; 26:2052-60
12. Williams GT, Farzaneh F. Are snoRNAs and snoRNA host genes new players in cancer? Nature Rev Cancer 2012; 12:84-8
13. Scott MS, Avolio F, Ono M, Lamond AI, Barton GJ. Human miRNA precursors with box H/ACA snoRNA features. Plos Comput Biol 2009; 5:e1000507
14. Scott MS, Ono M. From snoRNA to miRNA: dual function regulatory noncoding RNAs. Biochimie 2011; 93:1987-92
15. Brameier M, Herwig A, Reinhardt R, Walter L, Gruber J. Human box C/D snoRNAs with miRNA like functions: Expanding the range of regulatory RNAs. Nucleic Acids Res 2011; 39:675-86
16. Kino T, Hurt DE, Ichijo T, Nader N, Chrousos GP. Noncoding RNA Gas5 is a growth arrest-and starvation-associated repressor of the glucocorticoid receptor. Sci Signal 2010; 3:ra8
17. Smith CM, Steitz JA. Classification of gas5 as a multi-small-nucleolar-RNA (snoRNA) host gene and a member of the 5'-terminal oligopyrimidine gene family reveals common features of snoRNA host genes. Mol Cell Biol 1998; 18:6897-909
18. Nguyen VT, Kiss TS, Michels AA, Bensaude O. 7SK small nuclear RNA binds to and inhibits the activity of CDK9/cyclin T complexes. Nature 2001; 414:322-5
19. Askarian-Amiri ME, Crawford J, French JD, et al. SNORD-host RNA Zfas1 is a regulator of mammary development and a potential marker for breast cancer. RNA 2011; 17:878-91
20. Mourtada-Maarabouni M, Hasan AM, Farzaneh F, Williams GT. Inhibition of human T-cell proliferation by mammalian target of rapamycin (mTOR) antagonists requires noncoding RNA growth-arrest-specific transcript 5 (GAS5). Mol Pharmacol 2010; 78:19-28
21. Williams GT, Mourtada-Maarabouni M, Farzaneh F. A critical role for non-coding RNA GAS5 in growth arrest and rapamycin inhibition in human T-lymphocytes. Biochem Soc Trans 2011; 39:482-6
22. Peponi E, Drakos E, Reyes G, Leventaki V, Rassidakis GZ, Medeiros LJ. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. Am J Pathol 2006; 169: 2171-80
23. Hess G. Temsirolimus for the treatment of mantle cell lymphoma. Exp Rev Hematol 2009; 2:631-40
24. Jeon H, Kim C, Yoshino T, Akagi T. Establishment and characterization of a mantle cell lymphoma cell line. Br J Haematol 1998; 102:1323-6
25. Rubio-Moscardo F, Blesa D, Mestre C, et al. Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes. Blood 2005; 106:3214-22
26. Bedner E, Smolewski P, Amstad P, Darzynkiewicz Z. Activation of caspases measured in situ by binding of fluorochrome-labeled inhibitors of caspases (FLICA): Correlation with DNA fragmentation. Exp Cell Res 2000; 259:308-13
27. Smolewski P, Bedner E, Du L, et al. Detection of caspases activation by fluorochrome-labeled inhibitors: Multiparameter analysis by laser scanning cytometry. Cytometry 2001; 44:73-82
28. Abraham R, Wiederrecht G. Immunopharmacology of rapamycin. Annu Rev Immunol 1996; 14:483-510
29. Ma WW, Jimeno A. Temsirolimus. Drugs Today 2007; 43:659-69
30. Majewski M, Korecka M, Joergensen J, et al. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation 2003; 75:1710-7
31. Brunn G, Fadden P, Haystead T, Lawrence J. The mammalian target of rapamycin phosphorylates sites having a (Ser/Thr)-Pro motif and is activated by antibodies to a region near its COOH terminus. J Biol Chem 1997; 272:32547-50
32. Fingar D, Richardson C, Tee A, Cheatham L, Tsou C, Blenis J. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 2004; 24:200-16
33. Tee A, Blenis J. mTOR, translational control and human disease. Semin Cell Dev Biol 2005; 16:29-37
34. Meyuhas O. Synthesis of the translational apparatus is regulated at the translational level. Eur J Biochem 2000; 267:6321-30
35. Rosenwald I, Lazariskaratzas A, Sonenberg N, Schmidt E. Elevated levels of cyclin D1 protein in response to increased expression of eukaryotic initiation-factor 4e. Mol Cell Biol 1993; 13:7358-63
36. Zimmer S, Debenedetti A, Graff J. Translational control of malignancy: The mRNA cap-binding protein, eIF-4E, as a central regulator of tumor formation, growth, invasion and metastasis. Anticancer Res 2000; 20:1343-51
37. Nourse J, Firpo E, Flanagan W, et al. Interleukin-2-mediated elimination of the P27(kip1) cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 1994; 372:570-3
38. Feng Z, Zhang H, Levine A, Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci U S A 2005; 102:8204-9.